Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced cancer; including metastatic, locally advanced or relapsed not amenable for curative treatment.~* Mini.mental status examination results within normal limits.~* Informed consent.~* Estimated life expectancy of at least one month.~* Hemoglobin \>= 9 g/dl.~* Asthenia \>= 5 (0-10; numeric verbal scale).~Exclusion Criteria:~* History of psychosis.~* Structured suicidal ideation.~* Severe anxiety.~* Severe renal, hepatic or cardiac (arrythmia, hypertension, ischemic heart disease) failure.~* Simultaneous treatment with drugs that may interact with methylphenidate as: coumarinics, anticonvulsivants (phenobarbital, phenitoin, primidone), phenylbutazone, inhibitors of mono-amine-oxidase, guanethidine.~* History of glaucoma.~* Hyperthyroidism.~* History of hypersensibility to methylphenidate.~* Clinical suspicion of: infection, hypercalcemia, hypothyroidism or renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methylphenidate (Type: EXPERIMENTAL): methylphenidate (pill) p.o. 15 to 25 mg daily for six days
- placebo (Type: PLACEBO_COMPARATOR): the same number of pills (p.o.) than methylphenidate for six days

Based on this trial design, predict the completion outcome and termination type (if applicable).